Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Calon A, Lonardo E, Berenguer-Llergo A et al (2015) Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47(4):320–329. https://doi.org/10.1038/ng.3225

Article  CAS  PubMed  Google Scholar 

Dulskas A, Gaizauskas V, Kildusiene I, Samalavicius NE, Smailyte G (2020) Improvement of survival over time for colorectal cancer patients: a population-based study. J Clin Med 9(12):4038. https://doi.org/10.3390/jcm9124038

Article  PubMed  PubMed Central  Google Scholar 

ASGE Standards of Practice Committee, Fisher DA, Shergill AK et al (2013) Role of endoscopy in the staging and management of colorectal cancer. Gastrointest Endosc 78:8–12. https://doi.org/10.1016/j.gie.2013.04.163

Article  Google Scholar 

Kahi CJ, Boland CR, Dominitz JA et al (2016) Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastroenterology 150:758–768.e711. https://doi.org/10.1053/j.gastro.2016.01.001.

Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD (2000) Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 92:557–563

Article  CAS  PubMed  Google Scholar 

Garborg K, Holme Ø, Løberg M, Kalager M, Adami HO, Bretthauer M (2013) Current status of screening for colorectal cancer. Ann Oncol 24:1963–1972. https://doi.org/10.1093/annonc/mdt157

Article  CAS  PubMed  Google Scholar 

Anderson JC, Fortinsky RH, Kleppinger A, Merz-Beyus AB, Huntington CG 3rd, Lagarde S (2011) Predictors of compliance with free endoscopic colorectal cancer screening in uninsured adults. J Gen Intern Med 26:875–880. https://doi.org/10.1007/s11606-011-1716-7

Article  PubMed  PubMed Central  Google Scholar 

Niv Y, Sperber AD (1995) Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy. Am J Gastroenterol 90:1974–1977

CAS  PubMed  Google Scholar 

Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) Improving the fecal occult-blood test. N Engl J Med 334:1607–1608. https://doi.org/10.1056/NEJM199606133342414

Article  CAS  PubMed  Google Scholar 

Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334:155–159. https://doi.org/10.1056/NEJM199601183340304

Article  CAS  PubMed  Google Scholar 

Lieberman DA, Weiss DG, Bond JH et al (2000) Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med 343(3):162–168. https://doi.org/10.1056/NEJM2000072034303018

Article  CAS  PubMed  Google Scholar 

Calderwood AH, Lasser KE, Roy HK (2016) Colon adenoma features and their impact on risk of future advanced adenomas and colorectal cancer. World J Gastrointest Oncol 8(12):826–834. https://doi.org/10.4251/wjgo.v8.i12.826

Article  PubMed  PubMed Central  Google Scholar 

Hisabe T, Hirai F, Matsui T (2014) Development and progression of colorectal cancer based on follow-up analysis. Dig Endosc 26:73–77. https://doi.org/10.1111/den.1227610

Article  PubMed  Google Scholar 

Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116(3):544–573. https://doi.org/10.1002/cncr.2476011

Article  PubMed  Google Scholar 

Dulskas A, Poskus T, Kildusiene I et al (2021) National colorectal cancer screening program in Lithuania: description of the 5-year performance on population level. Cancers (Basel) 13(5):1129. https://doi.org/10.3390/cancers13051129.PMID:33800772;PMCID:PMC7961359

Article  PubMed  Google Scholar 

Meklin J, SyrjÄnen K, Eskelinen M (2020) Fecal occult blood tests in colorectal cancer screening: systematic review and meta-analysis of traditional and new-generation fecal immunochemical tests. Anticancer Res 40(7):3591–3604. https://doi.org/10.21873/anticanres.14349

Article  CAS  PubMed  Google Scholar 

Park HJ, Ahn JY, Jung HY et al (2014) Clinical characteristics and outcomes for gastric cancer patients aged 18–30 years. Gastric Cancer 17:649–660

Nam DH, Lee YK, Park JC et al (2013) Prognostic value of early postoperative tumor marker response in gastric cancer. Ann Surg Oncol 20:3905–3911

Parchur AK, Sharma G, Jagtap JM et al (2018) Vascular in⁃terventional radiology⁃guided photothermal therapy of colorectal cancer liver metastasis with theranostic gold nanorods. ACS Nano 12(7):6597–6611

Türk G, Eldem G, Kılıçkap S et al (2019) Outcomes of radioembolization in patients with chemorefractory colorectal cancer liver metastasis: a single-center experience. J Gastrointest Cancer 50(2):236–243. https://doi.org/10.1007/s12029-018-0053-z

Article  PubMed  Google Scholar 

Baidoun F, Elshiwy K, Elkeraie Y et al (2021) Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets 22:998–1009

Adam R, de Gramont A, Figueras J et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41(9):729–41. https://doi.org/10.1016/j.ctrv.2015.06.006

Zhang S-Y, Lin M, Zhang H-B (2015) Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19–9 for colorectal carcinoma. Int J Clin Exp Pathol 8:9404–9409

PubMed  PubMed Central  Google Scholar 

Filella X, Molina R, Grau JJ et al (1992) Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 216:55–59

Zhang L-N, OuYang P-Y, Xiao W-W et al (2015) Elevated CA19-9 as the most significant prognostic factor in locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Medicine 94:e1793

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keller G, Vogelsang H, Becker I et al (2004) Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 41(6):e89. https://doi.org/10.1136/jmg.2003.015594

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Z, Zhang N (2014) Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Onc 12:397. https://doi.org/10.1186/1477-7819-12-397

Article  Google Scholar